TY - GEN AU - Feng,Po-Hao AU - Chen,Kuan-Yuan AU - Huang,Yu-Chen AU - Luo,Ching-Shan AU - Wu,Shen Ming AU - Chen,Tzu-Tao AU - Lee,Chun-Nin AU - Yeh,Chi-Tai AU - Chuang,Hsiao-Chi AU - Han,Chia-Li AU - Lin,Chiou-Feng AU - Lee,Wei-Hwa AU - Kuo,Chih-Hsi AU - Lee,Kang-Yun TI - Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma SN - 1556-1380 PY - 2019///0903 KW - Adenocarcinoma KW - drug therapy KW - Adult KW - Aged KW - Aged, 80 and over KW - Antineoplastic Combined Chemotherapy Protocols KW - therapeutic use KW - Bevacizumab KW - administration & dosage KW - Brain Neoplasms KW - immunology KW - Calgranulin B KW - metabolism KW - Carcinoma, Non-Small-Cell Lung KW - ErbB Receptors KW - genetics KW - Erlotinib Hydrochloride KW - Female KW - Follow-Up Studies KW - Gefitinib KW - pharmacology KW - Humans KW - Lung Neoplasms KW - Male KW - Middle Aged KW - Mutation KW - Myeloid-Derived Suppressor Cells KW - drug effects KW - Prognosis KW - Survival Rate N1 - Publication Type: Journal Article; Research Support, Non-U.S. Gov't UR - https://doi.org/10.1016/j.jtho.2018.03.032 ER -